NCT00171301View on ClinicalTrials.gov

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

PHASE4CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Beta-thalassemia MajorHemosiderosisIron OverloadRare Anemia
Interventions
DRUG

Deferasirox

Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.

Trial Locations (5)

Unknown

Novartis Investigative Site, Cairo

Novartis Investigative Site, Beirut

Novartis Investigative Site, Muscat

Novartis Investigative Site, Riyadh

Novartis Investigative Site, Damascus

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY